Best Stock to buy: This MRSA-related stock is a strong buy at current prices!
Today's Financial News - Posted March 17, 2009
MRSA infections are on the rise. So are lawsuits against prison systems and healthcare providers. Good news for one small biotech company that just landed a MAJOR approval.
by J. Christoph Amberger
Baltimore—TFN: We predicted this in January. Infections with the dangerous Methicillin-resistant Staphylococcus aureus, or MRSA, are fast becoming the next cash cow for litigation lawyers.
According to LeHighValleyLive.com, four more men have filed Federal lawsuits against Northampton County Prison and its health care provider, claiming they were not properly cared for after contracting antibiotic-resistant MRSA infections. They filed suit on March 5, joining others who have brought similar lawsuits concerning against this particular prison and its medical provider.
Prisons all over the country have increasingly become targets for litigation lawyers. (See also “30 inmates file lawsuit against PA prison: Prepare for a wave of MRSA litigation”.) Hospitals, universities, and health systems now fear that they will be the next target for tens of millions in “Jackpot Justice”.
MRSA itself has been making news headlines all week: It’s been found in pork, in ocean water, on ambulance stethocopes, cellphones brought into hospitals.
Good news for us… and for those TFN Hot Stock Confidential members who bought shares in the anti-MRSA company we recommended: A major western country known for its centralized approach to healthcare has just issued a medical device license the company’s rapid-detection test. Even better, the stock still trades at just above $6.
Find out on how you can take advantage of the buying opportunity created by last month’s stock market collapse!
Read our special report right here!
Next Article: 2009: The year of the letdown
One Response to “Best Stock to buy: This MRSA-related stock is a strong buy at current prices!”
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down
March 17th, 2009 at 6:48 pm
Along with the company that you are talking about here is one for to look at it is a smallcap stock that has a cleaner that is APPROVED to say on the label that it kills MRSA and VRE and it is a catagory four rating with the E.P.A. which means there are no safety warnings or precaustions needed to use it. The company is called Anpath Group, and trades under the symbol ANPG. The CEO of this company is Lyodd Breadlove who previously was the Sr-VP of sales and distribution for Steris when the revenues of that company went from $30m a year to over $800m a year.